IC 14

Drug Profile

IC 14

Alternative Names: Anti-CD14 antibody

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ICOS Corporation
  • Developer ICOS Corporation; Implicit Bioscience; University of Washington
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action CD14 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury
  • Phase Unknown Adult respiratory distress syndrome
  • Discontinued Septic shock

Most Recent Events

  • 11 Jan 2017 Implicit Bioscience plans a phase II trial for Adult respiratory distress syndrome in USA (IV) (NCT03017547)
  • 09 Jan 2017 Investigation in Adult respiratory distress syndrome in USA (IV) before January 2017
  • 24 Feb 2009 IC 14 licensed to Implicit Bioscience worldwide for the treatment of Acute lung injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top